

Remarks

By the present amendment, claims 1, 2, 4, 5, 7, 8, 10, 11, 13-16, 22 and 23 have been amended and no claims have been deleted, rendering 1-23 claims pending in the present application. The amendments to the claims have been made without prejudice and without acquiescing to any of the Examiner's objections. Applicant reserves the right to pursue any of the deleted subject matter in a further divisional, continuation or continuation-in-part application.

The Official Action dated November 20, 2002 has been carefully considered. It is believed that the amended claims submitted herewith and the following comments represent a complete response to the Examiner's rejections and place the present application in condition for allowance. Reconsideration is respectfully requested.

Election/Restriction Requirement

Claims 5, 11 and 13-15 have been amended to delete reference to SEQ ID NOS: 1, 4 and 6 in view of the Restriction Requirement.

Drawings

We are enclosing herewith revised Figures 1-4 and 9 to overcome the objection under 37 CFR §1.84(h)(2) that certain Figures are not labeled separately. Former Figures 1-4 and 9 have been relabeled Figures 1A-D; 2A-C; 3A-B; 4A-E and 9A-D.

Claim Objections - Informalities

The Examiner has requested that in Claims 5, 11, 14 (b)-(e) and Claim 15 (a) (1)-(4), the phrase "a nucleic acid sequence of" is replaced with "the nucleic acid sequence". While we believe it is not appropriate to amend the claims in every instance these claims recite "a nucleic acid sequence", we have amended these claims in accordance with the Examiner's request whenever appropriate. These claims have also been amended to ensure that they are not directed to non-elected inventions.

The Examiner has requested that in claims 14 and 15 the phrase "isolated nucleic acid sequence" is replaced with "isolated nucleic acid molecule". Claims 14 and 15 have been amended in accordance with the Examiner's request.

The Examiner has requested that in claims 22 and 23 the phrase "comprising a nucleic acid sequence" is replaced with the phrase "the nucleic acid sequence". Claims 22 and 23 have been amended in accordance with the Examiner's request.

Claims 5, 11, 14 and 15 have also been amended to correct the spelling of "complementary".

35 U.S.C. §112, first paragraph

(a) Written Description

The Examiner has objected to claims 1-23 under 35 U.S.C. §112, first paragraph as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. We respectfully disagree with the Examiner for the reasons that follow.

Applicants submit that the specification conveys with reasonably clarity to those skilled in the art that Applicants were in possession of the invention as now claimed at the time the application was filed. We will discuss the method and composition claims separately.

Composition claims 14-23 are limited to a flax promoter having a nucleic acid sequence shown in SEQ ID NO:8 (Figure 4). The claim also covers sequences that are complementary to the sequence as SEQ ID NO:8; sequences that have substantial sequence homology to SEQ ID NO:8; sequences that are analogs to SEQ ID NO:8 and sequences that hybridize to SEQ ID NO:8 under stringent hybridization conditions. Applicants were the first to isolate the promoter having the sequence shown in SEQ ID NO:8. As a result of Applicants' invention, one of skill in the art,

having read the disclosure of the present application, could readily isolate or prepare modifications to the sequence shown in SEQ ID NO:8 as provided in the claim. In particular, the disclosure provides on pages 10-12 examples of modifications that can be made to the sequence in order to prepare the claimed sequences. Further, we strongly submit that it would be unfair to limit the Applicants to the particular sequence as SEQ ID NO:8 as those skilled in the art could readily modify the sequence in order to circumvent the claim. In addition, Applicants have isolated four flax seed-specific promoters which is a representative number of species to demonstrate that Applicants are entitled to the scope of claim as currently pending. It is worth quoting from *in Re Goffe*:

"to provide effective incentives, claims must adequately protect inventors. To demand that the first to disclose shall limit his claims to what he has found will work or to materials which meet the guidelines specified for "preferred" materials in a process such as the one herein involved would not serve the constitutional purpose of promoting progress in the useful arts." (*in Re Goffe*, 542 F.2d 564, 567, 191 USPQ 429, 431 (CCPA 1976)).

Claims 1-13 relate to methods for the expression of a nucleic acid sequence of interest in flax seeds using a seed-specific promoter obtained from flax as well as flax plants and flax seeds prepared by the method. We respectfully submit that the independent method claims 1, 7 and 13 do not need to be limited to particular flax promoters. As mentioned above, in the present application, the Applicants have illustrated the effectiveness of the method of their invention through using four different flax seed promoters. Accordingly, we submit that the description of four different promoters in the method of the invention is sufficient to indicate that Applicants have possession of the claimed invention.

We point out to the Examiner that in the training materials that were published on March 1, 2000 that accompanied the Written Description Guidelines, there is an example, Example 18, that addresses the situation wherein the invention relates to a

method that employs a nucleic acid molecule. In that case, they provided only one example with a specific nucleic acid molecule and it was held that "the single embodiment is representative of the genus". Consequently, in the present case, we respectfully submit that four embodiments are represented of the genus and that the claims meet the Written Description requirements.

(b) Enablement

The Examiner has objected to claims 1-23 under 35 U.S.C. §112, first paragraph, alleging that the specification is only enabling with respect to SEQ ID NO:8. We respectfully disagree with the Examiner for the reasons that follow.

The requirement of enabling disclosure does not mean that the applicant must describe all actual embodiments. How a teaching is set forth, by specific example or broad terminology, is not important (*in Re Marzocchi*, 439 F.2d 220, 223-24 169 USPQ 367, 370 (CCPA 1971)). As concerns the breadth of a claim relevant to enablement, the only relevant concern should be whether the scope of enablement provided to one skilled in the art by the disclosure is commensurate with the scope of protection sought by the claims (*in Re Moore*, 439 F.2d 1232, 1236, 169 USPQ 236, 239 (CCPA 1971)). The scope of enablement must only bear a "reasonable correlation" to the scope of the claims (*in Re Fisher*, 427F.2d 833, 839, 166USPQ 18, 24 (CCPA 1970)).

Claims 5, 11, 14-23 relate to SEQ.ID.NO.:8 and to nucleic acid sequences that (i) are hybridizing thereto under stringent conditions; or (ii) have substantial sequence homology therewith; or (iii) are complementary thereto; or (iv) are an analog thereof. The Examiner has objected that the application is not enabling as the claimed nucleic acid sequences are described solely in terms of their function and not their structure. Applicant disagrees with the Examiner and respectfully submits that there exists in the art to which the invention pertains a well recognized correlation between: (i) the similarity in chemical structure of nucleic acid molecules and the ability of nucleic acid molecules to hybridize under stringent conditions; and (ii) the similarity in chemical

structure of nucleic acid molecules and the degree of homology between nucleic acid molecules; and (iii) the similarity in chemical structure of nucleic acid molecules and the degree of complementarity between nucleic acid molecules; and (iv) the similarity in chemical structure of nucleic acid molecules and their analogs. To support this assertion Applicant herewith encloses the following textbook reference for the Examiner's consideration: Lewin B., 1994, Genes V Pages 111-113, which states *inter alia* that [the ability of two nucleic acid sequences to hybridize constitutes a precise test for their complementarity since only complementary sequences can form a duplex structure...] and [...the complementarity between single strands can be used to indicate the similarity between the original duplex molecules]. Furthermore Applicant points out that the terms "sequence that has substantial sequence homology", "sequence that hybridizes" and "a nucleic acid sequence which is an analog" have been defined in the specification to further clarify Applicant's intended meaning of these terms (see: Page 10, line 28 -Page 12 line 25). The claims recite nucleic acid molecules that (i) hybridize to SEQ.ID.NO.:8 under stringent hybridization conditions; or (ii) have substantial sequence similarity to SEQ.ID.NO.:8; or (iii) are complementary to SEQ.ID.NO.:8 or (iv) are an analog of SEQ.ID.NO.:8. The claims clearly do not recite any promoter capable directing seed-specific expression obtainable from flax.

The Examiner also points out that in certain instances limited nucleotide substitutions may result in significant functional changes (such as is the case Chamberland et al. and Donald et al. art cited by the Examiner). In response Applicant respectfully submits that such substitutions are the exception rather than the rule. It should be noted in this regard that the authors of the Chamberland et al. paper identified the legumin box within the promoter of the soybean β -conglycinin promoter as an element suspected to be important for promoter function prior to preparing promoter mutants comprising nucleotide substitutions within the legumin box and that furthermore the plant mutants that were obtained retain significant promoter activity. Similarly, in the Donald et al. paper mutations within the previously identified G, I, and GT boxes,

elements putatively important for promoter function within the *Arabidopsis thaliana* rbcS-1A promoter, were evaluated and again mutants typically retain promoter activity.

Thus we respectfully submit that the specification fully, clearly and concisely describes the claimed nucleic acid molecules and provides sufficient guidance to a person of ordinary skill in the art to make and use these molecules.

Claims 1-4, 6-10 and 12-13 are directed to methods for the expression of a nucleic acid sequence in of interest in flax seeds using a seed-specific promoter obtained from flax and the resultant flax plants and seeds. Applicant discloses 4 different seed-specific promoters isolated from flax. In addition the application teaches a person of ordinary skill in the art how to readily obtain additional seed specific promoters (see page 15, lines 10-32) and use such flax seed specific promoters in accordance with the present invention. Accordingly we respectfully submit that Applicant has demonstrated by using a representative number of seed specific promoters that such promoters are useful in the expression of a nucleic acid sequence under the control of a seed specific promoter in flax seeds. Applicant therefore is entitled to claim a method for the expression of a nucleic acid sequence using any flax seed specific promoter in flax seeds.

The Examiner has suggested to amend the claims to recite a "seed-preferred promoter" rather than a "seed-specific promoter". We thank the Examiner for his suggestion and have herewith amended the claims and the specification in accordance with this suggestion.

In view of the foregoing, we respectfully request that the objections to the claims under 35 U.S.C. §112, first paragraph be withdrawn.

35 U.S.C. §112, second paragraph

The Examiner has objected to claims 2-5, 8, 9, 11, 12 and 14-23 under 35 U.S.C. §112, second paragraph, as failing to particularly point out and distinctly claim the

subject matter which is regarded as the invention. Our comments to these objections are as follows.

The Examiner has objected to claim 2 'because it is unclear to what the claim is referring as to "characteristic conferred by said seed-specific promoter" is "conferred to said non-native nucleic acid sequence". We respectfully disagree with the Examiner as the claim is clear in that it is the seed-specific promoter that is conferring the expression characteristic to the non-native nucleic acid sequence of interest as opposed to the native nucleic acid sequence conferring the characteristic to the non-native nucleic acid sequence. Claims 2 and 3 are meant to specify that the seed-specific promoter confers a characteristic that it would normally confer on its native sequence to the nucleic acid sequence of interest.

The Examiner has objected to claim 4 for being improper Markush format. In response Applicant has herewith amended the claims to recite "is selected from the group of promoters consisting of..."

The Examiner has objected to claims 5, 11, 14 and 15 reciting "has substantial sequence homology to; "is an analog of a nucleic acid sequence" and "hybridizes under stringent hybridization conditions". Applicant agrees with the Examiner that all of these terms potentially could be unclear to a person of skill in the art, however we respectfully submit that in conjunction with the precise definition of each of these terms as set forth in the specification from Page 10, line 28 - Page 12, line 25 these terms will be readily understood by the skilled artisan. Thus the claims particularly point out and distinctly claim the subject matter which the applicant regards as his invention.

The Examiner has objected to claim 15 as being indefinite as it is unclear how the nucleic acid sequence at 15(a)(2) could hybridize to the nucleic acid sequence of 15(a)(2), itself. We agree with the Examiner and have revised the claims in

accordance with the Examiner's suggestion so that 15(a)(2) recites 15(a)(1); 15(a)(3) recites 15 (a)(1) or 15 (a)(2); and 15(a)(4) recites 15(a)(1) or 15(a)(2) or 15(a)(3).

In view of the foregoing, we respectfully request that the objections to the claims under 35 U.S.C. §112, second paragraph be withdrawn.

35 U.S.C. §102

The Examiner has objected to Claims 1,3, 5-9 and 11-23 as being anticipated by Jain et. (WO 98/18948). We respectfully disagree with the Examiner for the reasons that follow.

Jain et al. discloses two flax promoters sequences operably linked to two stearyl-acyl carrier protein desaturase (SAD) coding sequences from flax. In order for Jain et al. to anticipate the invention the disclosure must provide each and every element of the claim. While the SAD promoters disclosed in Jain et al. are capable of directing the expression of heterologous nucleic acid sequences in seed, significant expression is observed in other tissues as well. For example, Fig. 6 shows significant expression of SAD2 in young leaves and apices; mature leaves; stems; buds; half open flowers and flowers and Fig. 10 shows GUS activity, which, according to Jain et al. could be [...*easily detected in both leaves and seeds*] (see Page 21, Line 21). Furthermore Jain et al. state that [...*these promoters are useful in manipulating transgene expression in variety of tissues including seed*] (see: page 9, lines 25-26) and [...*these promoters were capable of expressing the uidA gene in various tissues...*] (see: page 21, line 6-7). Thus a person of skill in the art would when following the teachings of Jain et al. not expect to achieve expression seed-specific or seed preferred expression, as such term will be understood by a person of skill in the art having read the instant specification. In *Scripps Clinic & Research Foundation v. Genentech, Inc.* (927 F.2d 1565, 18 USPQ 2d 1001 Fed Cir:1991), the Court held that in order for there to be anticipation, the prior art must place the invention in the possession of the public by providing an enabling disclosure of how to make and use the claimed subject matter. Jain et al. clearly does not enable the production of seed-

specific expression of a nucleic acid sequence of interest. Consequently, Jain et al. cannot be said to anticipate the claims of the invention.

In view of the foregoing, we respectfully request that the objections to the claims under 35 U.S.C. §102 be withdrawn.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

The Commissioner is hereby authorized to charge any fee (including any claim fee) which may be required to our Deposit Account No. 02-2095.

In view of the foregoing comments, we respectfully submit that the application is in order for allowance and early indication of that effect is respectfully requested. Should the Examiner deem it beneficial to discuss the application in greater detail, he is kindly requested to contact the undersigned by telephone at (416) 957-1682 at his convenience.

Respectfully submitted,

Sarita. Chaudhary et al.

A handwritten signature in cursive script, appearing to read "M. Gravelle", is written over a horizontal line.

Micheline Gravelle
Registration No. 40,261

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada M5H 3Y2

(416) 364-7311

Version with markings to show changes made

In the Specification

Page 6, lines 24-32 have been amended as follows:

--Figures 1A-D show[s] the DNA sequence (SEQ.ID.NO.:1) of a flax genomic clone encoding a 16.0 kDa oleosin protein (SEQ.ID.NOS.:2 and 3).

Figures 2A-C show[s] the DNA sequence (SEQ.ID.NO.:4) of a flax genomic clone encoding a 18.6 kDa oleosin protein (SEQ.ID.NO.:5).

Figures 3A-B show[s] the DNA sequence (SEQ.ID.NO.:6) of a flax genomic clone encoding a 2S storage protein (SEQ.ID.NO.:7).

Figures 4A-E show[s] the DNA sequence (SEQ.ID.NO.:8) of a flax genomic clone encoding a 54.5 kDa legumin-like storage protein (SEQ.ID.NOS.:9-12).--

Page 7, lines 9-11 have been amended as follows:

--Figures 9A-D show[s] GUS expression in developing flax embryos and Arabidopsis seeds of plants transformed with a 2S protein gene promoter GUS fusion.--

Page 10, lines 7-10 have been amended as follows:

-- The terms "seed-specific promoter" or "seed-preferred promoter", both of which terms may be used interchangeably herein, mean that a gene expressed under the control of the promoter is predominantly expressed in plant seeds with no or no substantial expression, typically less than 5% of the overall expression level, in other plant tissues --.

In the Claims

Claims 1, 2, 4, 5, 7, 8, 10, 11, 13-16, 22 and 23 have been amended as follows:

1. (*amended*) A method for the expression of a nucleic acid sequence of interest in flax seeds comprising:

- (a) preparing a chimeric nucleic acid construct comprising in the 5' to 3' direction of transcription as operably linked components:
 - (1) a seed-preferred [specific] promoter obtained from flax; and
 - (2) said nucleic acid sequence of interest wherein said nucleic acid of interest is non-native to said seed-preferred [specific] promoter;
- (b) introducing said chimeric nucleic acid construct into a flax plant cell; and
- (c) growing said flax plant cell into a mature flax plant capable of setting seed

wherein said nucleic acid sequence of interest is expressed in the seed under the control of said seed-preferred [specific] promoter.

2 (*amended*). The method according to claim 1 wherein at least one expression characteristic conferred by said seed-preferred [specific] promoter to its native nucleic acid sequence is conferred to said non-native nucleic acid sequence.

4. (*amended*) The method according to claim 1 wherein said flax seed-preferred [specific] promoter is selected from the group of promoters consisting of [comprising,] oleosin promoters, 2S storage protein promoters and legumin-like seed-storage protein promoters.

5. (*amended*) The method according to claim 1 wherein said flax seed-preferred [specific] promoter comprises:

- (a) the [a] nucleic acid sequence as shown in [Figure 1 (SEQ.ID.NO.:1), Figure 2 (SEQ.ID.NO.:4), Figure 3 (SEQ.ID.NO.:6) or] Figure 4 (SEQ.ID.NO.:8) wherein T can also be U;

- (b) a nucleic acid sequence that is complementary [complimentary] to the nucleic acid sequence of (a);
- (c) a nucleic acid sequence that has substantial sequence homology to the nucleic acid sequence of (a) or (b);
- (d) a nucleic acid sequence that is an analog of the nucleic acid sequence of (a), (b) or (c); or
- (e) a nucleic acid sequence that hybridizes to the [a] nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.

7. (*amended*) Transgenic flax seed prepared according to a method comprising:

- (a) preparing a chimeric nucleic acid construct comprising in the 5' to 3' direction of transcription as operably linked components:
 - (1) a seed-preferred promoter obtained from flax; and
 - (2) a nucleic acid sequence of interest wherein said nucleic acid of interest is non-native to said seed-preferred promoter;
- (b) introducing said chimeric nucleic acid construct into a flax plant cell; and
- (c) growing said flax plant cell into a mature flax plant capable of setting seed

wherein said nucleic acid sequence of interest is expressed in the seed under the control of said seed-preferred [specific] promoter.

8. (*amended*) Transgenic flax seed according to claim 7 wherein at least one expression characteristic conferred by said seed-preferred [specific] promoter to its native nucleic acid sequence is conferred to said non-native nucleic acid sequence.

10. (*amended*) Transgenic flax seed according to claim 8 wherein said seed-preferred [specific] promoter is a seed storage protein promoter, an oleosin promoter, a 2S storage protein promoter or a legumin-like seed-storage protein promoter.

11. (*amended*) Transgenic flax seed according to claim 8 wherein said seed-preferred promoter comprises:

- (a) the nucleic acid sequence as shown in [Figure 1 (SEQ.ID.NO.:1), Figure 2 (SEQ.ID.NO.:4), Figure 3 (SEQ.ID.NO.:6) or] Figure 4 (SEQ.ID.NO.:8) wherein T can also be U;
- (b) a nucleic acid sequence that is complementary [complimentary] to the nucleic acid sequence of (a);
- (c) a nucleic acid sequence that has substantial sequence homology to the nucleic acid sequence of (a) or (b);
- (d) a nucleic acid sequence that is an analog of the nucleic acid sequence of (a), (b) or (c); or
- (e) a nucleic acid sequence that hybridizes to the [a] nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.

13. (*amended*) Transgenic flax plants capable of setting seed prepared by a method a method comprising:

- (a) preparing a chimeric nucleic acid construct comprising in the 5' to 3' direction of transcription as operably linked components:
 - (1) a seed-preferred [specific] promoter obtained from flax; and
 - (2) a nucleic acid sequence of interest wherein said nucleic acid of interest is non-native to said seed-preferred [specific] promoter;

- (b) introducing said chimeric nucleic acid construct into a flax plant cell; and
- (c) growing said flax plant cell into a mature flax plant capable of setting seed

wherein said nucleic acid sequence of interest is expressed in the seed under the control of said seed-preferred [specific] promoter.

14. (*amended*) An isolated nucleic acid molecule capable of directing seed-preferred [specific] expression in a plant comprising:

- (a) the [a] nucleic acid sequence as shown in [Figure 1 (SEQ.ID.NO.:1), Figure 2 (SEQ.ID.NO.:4), Figure 3 (SEQ.ID.NO.:6) or] Figure 4 (SEQ.ID.NO.:8) wherein T can also be U;
- (b) the nucleic acid sequence that is complementary [complimentary] to the nucleic acid sequence of (a);
- (c) a nucleic acid sequence that has substantial sequence homology to the nucleic acid sequence of (a) or (b); or
- (d) a nucleic acid sequence that is an analog of the nucleic acid sequence of (a), (b) or (c); or
- (e) a nucleic acid sequence that hybridizes to the [a] nucleic acid sequence of (a), (b), (c) or (d) under stringent hybridization conditions.

15. (*amended*) An isolated chimeric nucleic acid molecule comprising:

- (a) a first nucleic acid sequence comprising a seed-preferred promoter obtained from flax which comprises:
 - (1) the nucleic acid sequence as shown in [Figure 1 (SEQ.ID.NO.:1), Figure 2 (SEQ.ID.NO.:4), Figure 3 (SEQ.ID.NO.:6) or] Figure 4 (SEQ.ID.NO.:8) wherein T can also be U;

- (2) a nucleic acid sequence that hybridizes to the nucleic acid sequence of (a)(1) under stringent hybridization conditions;
 - (3) a nucleic acid sequence that is complementary [complimentary] to the nucleic acid sequence of (a)(1) or (a)(2); or
 - (4) a nucleic acid sequence that has substantial sequence homology to the nucleic acid sequence of (a)(1); (a)(2) or (a)(3); and
- (b) a second nucleic acid sequence non-native to said flax seed-preferred [specific] promoter.

16. (*amended*) A method for the expression of a nucleic acid sequence of interest in a plant seed comprising:

- (a) introducing the chimeric nucleic acid molecule according to claim 15 into a plant cell; and
- (b) growing said plant cell into a mature plant capable of setting seed,

wherein the second nucleic acid sequence is expressed in the seed under the control of the seed-preferred [specific] promoter.

22 (*amended*). A recombinant expression vector comprising the [a] nucleic acid sequence according to claim 14.

23. (*amended*) A recombinant expression vector comprising the [a] nucleic acid sequence according to claim 15.

FIGURE 1A

1 ttcaaaacccgattcccgaggcgccctattgaagatatgggggaagtctcgacgagatcgatgcgggtcgagtgcctatg 80
81 gtgatggtgccgtttggggggaggatgagcgagatagccaagactagcattccgttcccacacagagttgggaatttcta 160
161 ccaaatccaaacacttgctgtattggagcgacgatagggacgcgggaaacacacatccgttggatcaggagttgtacgatg 240
241 atctcgagccttatgtgtcgaagaatccgaggtatgcttacgtgaactacagggatctcgacatcgggatgaatggagga 320
321 ggtgaagggatgagaagggtactttatggtgaggctaagggtgtgggggagaaagtactttggggccaactttgatcggtt 400
401 ggttcgggtgaagacgattgttgatcccaataaatgtgttcgaaacgagcagagcattccctcaattccaactcgggttat 480
481 aaggatcaatgatcaatgagaattttccctttcccaatgtgattacaagttctattgggtcagctttctcaactgctcctat 560
561 tcatttagattaataacaactatttaatttaccagccttttatccggcccggttgccgattttattttcttaagtttt 640
641 agatgaaatgaaaccgatttttagttttattgagatgagattaatcttaatttgcttgaaatttactcacgggtgatgtga 720
721 tatttggaattaaactaaaatgataaaatcggataaaaaataatatttataaataaataacataaaacataagaacaata 800
801 aaataaaataatttttaatttttccctgtgttttctgtatcacatctcttcttacttctttaaaggcctt 880
881 ttcaattatcacttaattaaaatacaatagataaaaatcggttaattctataaacattaaacctatacacttgcacggtgaacaat 960
961 caatatgataataataataataataattcaattatttaattataaaagtttatgcggtcagtt 1040
1041 tctgcaagctccgagctccttgtcatcgttagtttctcggtctcaagggtataacgactcggagcgagccctttgct 1120
1121 tccaatggacgggttgcatcttctgcgctcgttgagctcgattggcggtgcatgctgaggttcctacaaaaaaac 1200
1201 cctaaactagagggtgattaggggtgaaattaggggttgccctgggttccattgtccaaaagtttttagtcaacttaaaaaac 1280
1281 agacttaaaatttttatgcttcaaaaatagttttatctgtattatattagcgtgttaattagcttcttgacaatggggccggacgg 1360

FIGURE 1B

1361 gtacggattcgggaccccgatccccgccatagtgttaatggctcaactgccaagtccaagtcagcattggaccgaaattattggac 1440

1441 acgaagtactaatgtgaaaaacttttacatttgttttacttttaataactatgctatttttcaaaatttgaacttttaatt 1520

1521 actatgtttttatatagtttagtatactttaattttatgcaaaattcatctaattgtattaaactattttcgcattccgtag 1600

1601 ctaattatttcgaaggcaagtcaaaagtgtattgtggactatgtgagctaataattgaacctttatctctcccaaccactc 1680

1681 aagttaattgaaccaaactcgatcggttgggttttcgagctattttcgagccattgttgttatatgcacgtgagatatcaag 1760

1761 attgacccgaacacttttattatgataatgtagaaaaaagaaacatatatttctaagactacatgcatgcaaaagtgaacccct 1840

1841 gcatggaaagctgctcaacacgttggcagtagactccccgcacgtgtccattccacctcatcaccctccccaccgttcac 1920

1921 ctcttattatcacacaatcaatcaatcctactctctccatactcgaacaaatccgaccaacttataccaatattccca 2000

2001 aacttgattaaatttctcagcaat ATG GAT CAG ACG CAC CAG ACA TAC GCC GGA ACC ACG CAG AAC 2065

1 M D Q T H Q T Y A G T T Q N 14

2066 CCG AGC TAT GGC GGC GGC ACA ATG TAC CAG CAG CAG CCG AGG TCT TAC CAG GCG 2125

15 P S Y G G G T M Y Q Q Q Q P R S Y Q A 34

2126 GTG AAG GCG GCC ACT GCA GCC ACC GCG GGT GGA TCC CTC ATC GTT CTG TCC GGT CTC ATC 2185

35 V K A A T A A T A G G S L I V L S G L I 54

2186 CTT ACG GCC ACC GTC ATT TCA CTC ATC ATA GCC ACC CCT CTC CTY GTC ATC TTC AGC CCT 2245

55 L T A T V I S L I I A T P L L V I F S P 74

2246 GTT CTT GTC CCG GCT CTC ATC ACC GTC GGG CTC TTG ATC ACC GGG TTT CTT GCT TCC GGT 2305

75 V L V P A L I T V G L L I T G F L A S G 94

2306 GGG TTC GGA GTC GCC GTC ACC GTC TTG TCC TGG ATC TAT AG gtagtataagctttggactt 2370

95 G F G V A A V T V L S W I Y R 109

2371 tagtattgttataaaatacataaagctgattttatgaacatggatctctcccaacaagaggttatttaaatgcattctcggtctg 2450

22451	actcgatcggttggttttgagctactcgtgcacaatggtcgggtcggtctggatctgttatactaataatttgggaagcc	2530
22531	tgaagtttccattgttctgcccccaacttcccactaccttttgaggggtttaagaagccatacaaaactaattatgaatccct	2610
22611	cccaacaactcagaactcgagtcagtgggttgtgacggttctctataaaacatttcgaaaaatctttgttccaatgaacgtag	2690
22691	aaatgaccatgcttgatgattgtgggtcttataag	2756
110	Y V T G G H P A G G	119
22757	GAT TCG CTG GAC CAG GCT AGG TCG AAG CTG GCC GGA AAG GCC AGG GAG GTG AAG GAC AGG	2816
120	D S L D Q A R S K L A G K A R E V K D R	139
22817	GCG TCG GAG TTC GCA CAG CAG CAT GTC ACA GGT GGT CAA CAG ACC TCT TAA agagagtcctct	2879
140	A S E F A Q Q H V T G G Q Q T S *	156
22880	agttaaattggtcttctgtttctgttctgttctgtggcggtctgttaaactctctttttaagtgtgctgttttcttcttctcgtgt	2959
22960	gttgtaagtgaagtgtaatcgaagttccaaagtggagatgttttgtaacgatgatgttttctaataatcagagataattaa	3039
33040	aagggttgctaatttagtatcgtctgatctcggaccaaaactcgcaagtaaaaattgcagaggatgagttgtacagaaca	3119
33120	agcgtgcattgttctggaagtccatctctcttgagccgaccttgttcttgcttcgagtttcgccaaagtccactagacaaatgtt	3199
33200	acgagttaagcctctgtcaaacagatcgcttagcgtcccagaaaacaccagatttttcgaaaaccatcggggatcaatt	3279
33280	ttcgattccaattccgatcttgggaagtacttgaaacagaagcatgatgctaaaaagataataagaaaaatcgaagcctagaaaaag	3359
33360	ttgtacagaaagcaacaagtcaaaaatatagatcaactttcaaaagtttcaaaattacatctttacagaccccccaaaaatgaca	3439
33440	gttaacagaagtcgactaaaacagaaaaccagccagcttcacctggaatgaaggagcctttgatcaatcccatcctagcttcat	3519
33520	tccctttgaaattgcagacagagctctcatctctgctaaagctggtggttattctttaacctgtcaatcaataagcatga	3599
33600	actaacattggacaccttcacctcgccggaattgctcgaaaaatcagtgagcggaggttttacctgtgtgtgtagtaacctctc	3679

FIGURE 1D

3680 tccttgataaaaatctggaaattccggcatcaactactgccacctttctgcttaaggtgattttatcaccaaggctga 3759
3760 gcgtgattccttgctgtccgaatcctgatgtatccactgagctttccatctccttctccaggcttatgttc 3839
3840 accaatgcgtcctcgccgaacacactctttggcgtaaaagtccgagccaggaatccacactctccatcaagtgcagacct 3919
3920 gcaaaccccaataaagaacacacaaactccaaaagtcaacgatcaattctccgccttttatgaagaaaaaggaaacttctgggt 3999
4000 acttacggtgccgtcagacacttcataattttagacttgatgatatggtccaggaattccttctctgttctgaattgtgt 4079
4080 gttacagcaacctgacagacagaaaagataatcgcaaatttaagatactgggatgactaggcacagagaaatgaaatctaa 4159
4160 ttctagaagtaaaaccttatlttccattcaaatctgtgccacatatagtcgggaacgcagcatccgagcaagaagcaggag 4239
4240 agatgtaatccatgatatcgatgtggatatcgttgaggacgacacaactgaacgttccatcacattgg 4305

FIGURE 2A

1 tctagacatttgacataaaccgaattcaaa^{R1}gaacacacacattgactaacacccaaaaaagaaatagagtagtgaaatttggg 80
81 agattaaaaa^{R2}atagaaacaaactgattcttagaaagaagagatgattaggtgcttccagttcggctctgtcaggaaatcga 160
161 gatgttcaacttattacattgtcgatttcacatctcccaattgtcctggttcccttactgtccgacgcttttttgaatcccag 240
241 ttaattcccatcaagtcttcttcagctgctagctcccaacatggagcgtgagctctactcgttcacatgggg 320
321 catcgcaaagggttgccttcatgttctgtaccagccagccaccgcctcttggttgtgtggacaattgcggtgaagc 400
401 gcgcaagttgacatcccatagtctcgacacttcaccataatggatgtttaaaacgtatatcacgagtgcgatctacatgtc 480
481 ccatcacaccacataataagcaatagtttgggagcttttcataatttgaaacgggcattgacgacttgcctctcgataat 560
561 ttaatcttttttctctcagctgattgtgtgcaccattcgggtcagaagcacatcaaaagggatctctccatcgtagt 640
641 attgggtcgtgtatgatacgaagcagtcgatgaagtttctctaattgtcgcagctacaggctccgcaaaagaacccgcga 720
721 ggtagatcgtatgctagtaccacaaaaatcagtttctgtcgtagcggaatcaacacactagagactcaccctaattgcacatctcatg 800
801 tgtgatgaacagtttatcatttgtgagtcctaggggtcattgtcgcgatgacccaatgcacattgagcttatgatagaatttg 880
881 aataggaagcgttttccaccagatcacgaatatagctacccttttttctgggcgccaatttccggcatcctatcttccacc 960
961 acaacttaagatgcgatcggtaaggaaactcaccgaccacacacatcgaataatcttcggtgaccgggttcctgttgatca 1040
1041 agtccctcaatttccctcaacctagtcttcaatcgccgctagcgttatcccccgcatatggactttcatagcgcggagcgt 1120
1121 agccggagacgacgagcaagaaggatgagcggcgagattgcggctaaagaaacgagcttccctgccttgctctatggag 1200
1201 gcagatttctgagttgatggatgatttctgtgtgagacacttttaatttaagttgatttttttagcacttcattcacg 1280
1281 taattaaaataaa^{R4}atttccagtattttatattttatttcttaccgttatctaatatttttgaagattaaaaaactttgat^{R2}at 1360

FIGURE 2B

11361	aggcaagatcatgacacgtcgaagttaagtgaatgagactcctaacaaggtaataaacaagcaggttcataaacccgaatga	1440
	<div>R1</div>	
11441	ccttgatctttactaagcttgagatcattgaacataataataaatacgtttaatgaaagataagaactttaataataaaaat	1520
	<div>R4</div>	
11521	cattcaaaacgagaaaactgataacaaaaaagcaaacgccaacaaaataataagacggtggaaggatgatgcagagcc	1600
	<div>R5</div>	
11601	atccaccctttttccagtttcccttactgcttacttctctatgcatatcacaaagacgccccttgaaaacttgtagtcatg	1680
	<div>R5</div>	
11681	cagagcccttactgccaggtcacgcaccacggttactctatcacttctcctccttctccttttaaagaaccaccacgc	1760
	<div>R5</div>	
11761	cacctccctctcacaacactcataaaaaaacacctcttgcatttctcccaagttcaaatagttcacagctaagcaag	1840
	<div>R5</div>	
11841	aactcaacaaca	1903
1	M A D R T T Q P H Q V Q V H T Q H	17
11904	CAC TAT CCC ACC GGC GGC GCT TTC GGC CGT TAT GAA GGT GGA CTC AAA GGC GGT CCA CAT	1963
18 H	Y P T G G A F G R Y E G G L K G G P H	37
11964	CAC CAG CAA GGA TCA GGC AGC GGC CCA TCA GCT TCC AAG GTG TTA GCA GTC ATG ACC GCG	2023
38 H	Q G S G S G P S A S K V L A V M T A	57
2024	CTC CCC ATC GGC GGC ACC CTC CTT GCC TTG GCC GGG ATA ACC TTG GCT GGG ACG ATG ATC	2083
58 L	P I G G T L L A L A G I T L A G T M I	77
2084	GGG CTG GCG ATC ACC ACC CCG ATT TTT GTC ATC TGC AGC CCT GTT CTA GTC CCG GCC GCT	2143
78 G	L A I T T P I F V I C S P V L V P A A	97
2144	CTG CTC ATC GGC TTT GCC GTG AGC GCG TTT CTG GCC TCG GGG ATG GCC CTG ACA GGG	2203
98 L	L I G F A V S A F L A S G M A G L T G	117
2204	CTG ACC TCG CTG TCG TGG TTT GCG AGG TAT CTG CAG CAG GCT GGG CAG GGA GTT GGA GTG	2263
118 L	T S L S W F A R Y L Q Q A G Q G V G V	137
2264	GGG GTG CCG GAT AGT TTC GAG CAG GCG AAG AGG CGC ATG CAG GAT GCT GCT GGG TAT ATG	2323
138 G	V P D S F E Q A K R R M Q D A A G Y M	157

FIGURE 3A

1 tccaactatgtaggtcatalccatcatttttaattttttgggcaccattccaattcccatcttgccttttagggatgtgaatatga 80
5' primer (1) AT rich
81 acggccaaggtaagagataaaaaataatccaaatataaagcaagagagcccaagtaagataatccaaatgtacacttgta 160
AT rich
161 tcgccgaaattagtaaaatcacgcgcatattgtatttccacacattattaaaataccgtatatgtattggctgcatttgc 240
241 atgaataataactacgtgtaagcccaaaaagacccacgtgttagcccatgcaaaagttaaacactcacgacccattcctcagt 320
RY G box seed-specific
321 ctccactatataaaacccaccatcccccaatctttaccaaacccaccacacgactcacaactcgactctcacaccttaaaagaa 400
TATA 3' primer (1)
401 ccaatcaccacccaaaaaATGGCAAAGCTGATGAGCCTAGCAGCCGTAGCAACGCAGTTCTTCTCTGATCGTGTGGAC 480
1 M A K L M S L A A V A T Q F L F L I V V D 21
481 GCATCCGTCCGAACCCACAGTGATTATCGACGAGGAGACCAACCAAGGCCGCGTGGAGGCAAGTGGCAGGGACAGCAGC 560
22 A S V R T T V I I D E E T N Q G R G G K V A G T A A 48
561 AGTCTGCCGAGCAGATCCAGCAGCGAGACTTCTCTGAGGAGCTGCCAGCAGTTTCATGTGGGAGAAAGTCCAGAGGGGCG 640
49 V C E Q Q I Q Q R D F L R S C Q Q F M W E K V Q R G G 75
641 GCCACAGCCACTATTACAACCAGGGCCGTGGAGGAGGCGAACAGAGCCAGTACTTCGAACAGCTGTTGTGACGACCTTA 720
76 H S H Y Y N Q G R G G E Q S Q Y F E Q L F V T T L 101
721 AGCAATTGCCACCGCGGTGCACCATGCCAGGGGACTTGAAGCGTGCCATCGGCCAAATAGGCGAGGAAATCCAGCAGCA 800
102 S N C A P R C T M P G D L K R A I G Q M R Q E I Q Q Q 128
801 GGGACAGCAGCGGACAGCAGGAGGAGTTTCAGAGGTGGATCCAGCAAGCTAAACAAATCGCTAAGGACCTCCCCGGAC 880
129 G Q Q Q G Q Q Q E V Q R W I Q Q A K Q I A K D L P G Q 155

[illegible]

FIGURE 4A

10	20	30	40	50	60	70	80	90	100
ctcaagcatacggacaagggtaataacatagtcaccagaacataataaacaacaaagtgcagaagcaagataaaaaaattagctatggacattcagggttc									
110	120	130	140	150	160	170	180	190	200
atatggaaacatcattatcctagtccttgaccatcctcctcctgctctagttgagagccctgggactaacgagaggtcagttgggatagcagatccc									
210	220	230	240	250	260	270	280	290	300
ttatcctggactagcctttcttggtgtttcagagtccttcggtgccgcgtctacatctatctccatttaggtctgaagatgactcttcacaccaaagcagcttt									
310	320	330	340	350	360	370	380	390	400
aaggtctctactcctagcttgcaatacctggcttgcaatacctggagcatcgtgcacgatgattggatactgtggagaggagtggttgcctgatt									
410	420	430	440	450	460	470	480	490	500
tagagctcccggttgggtgatttgacttcgatttcagtttaggcttgtgaaatttttcaggttccattgtgaagccttttagagcttgagcttccttcca									
510	520	530	540	550	560	570	580	590	600
tgtttaatgccttgatcgaaattctcctagagaaaaaggaaagtcgatctctcgagtattgaaatcgaaagtcacattttttttcaacgtgtccaatcaatcca									
610	620	630	640	650	660	670	680	690	700
caaaacaagcagaagacaggtaatctttcatacttatactgacaagtaactgtcttaccgtcatgataataaacgtctcgttccttcaagaggggttttc									
710	720	730	740	750	760	770	780	790	800
cgacatccataaacgaccggagcctcatgaaagcattagggaagaacttttggttcttcttgcattggccttttatagggtgcagccgagctgcgccaattc									
810	820	830	840	850	860	870	880	890	900
ccgtccgactggctccgcaaaaatatcgaacggcaagttatggacttgaaccataactccacgggtattgagcaggacctattgtgaagactcatctcat									
910	920	930	940	950	960	970	980	990	1000
ggagcttcagaatgtggtgtcagcaaaccaatgaccgaaatccatcacatgacggacgtccagtggtgagcgaaacgaaacaggaaagcgccctatcttt									
1010	1020	1030	1040	1050	1060	1070	1080	1090	1100
cagagtcgtgagctccacaccggattccggcaactacgtgttggcagggttcgccgtattagagatatgttgaggcaagaccccatctgtgccactcgta									
1110	1120	1130	1140	1150	1160	1170	1180	1190	1200
caattacgagaggtgtttttttgtgattttcctaagtttctcgttgatggtgagctcataattctacatcgtatgggtctctcaacgtcgtttcctgtcat									

1210	1220	1230	1240	1250	1260	1270	1280	1290	1300
ctgatatcccgctcatttgcatccacgtgcccgcctcccggtgccaaagtccttaggtgtcatgcacgccaaaattggtggtggtggcggtgcccctgtgctt									
ABRE									
1310	1320	1330	1340	1350	1360	1370	1380	1390	1400
cttaccgatgggtgaaggttgagtttgggggtctcccgggcgatggttagtgggttgacgggttgggtgtgggttgacggcattgatcaattactcttgc									
R1									
1410	1420	1430	1440	1450	1460	1470	1480	1490	1500
ttcaaatcttttggcagaaaaaattcattagattagaactggaaaccagagtgatgagacggattaagtgcagattccaaacagaggttacatctcttaaga									
R2									
1510	1520	1530	1540	1550	1560	1570	1580	1590	1600
aataatgtaacccctttagactttatatatttgcgaattaaaaaaataatttaacttttagactttatatatagttttaactaaagtttaaccactcta									
R2									
1610	1620	1630	1640	1650	1660	1670	1680	1690	1700
ttatttatacgaaactatttgtatgtctccctctaaataaaacttgggtattgtgtttacagaacctataatcaaatcaataactcaactgaagttag									
R2									
1710	1720	1730	1740	1750	1760	1770	1780	1790	1800
tgcagttaattgaagggaattaacggccaaaatgcactagttattatcaaccgaatagattcacactagatggccattttccatcaatatcatcgccgttctt									
R2									
1810	1820	1830	1840	1850	1860	1870	1880	1890	1900
cttctgtccacatatccctctgaaacttgagagacacctgcacttcattgtctcttattacgtgtttacaaaaatgaaaccccatgcatccatgcaaaactgaa									
Legumin Vicilin									
1910	1920	1930	1940	1950	1960	1970	1980	1990	2000
gaatggcgcaagaacccttccctccatttcttatgtggcgaccatccatttcacatctcccgtatataaaacaccccccatcacttcacctagaacaatca									
CAAT									
2010	2020	2030	2040	2050	2060	2070	2080	2090	2100
tcactactgttatccatccaaaaagataccccaccATGGCTAGATCATCAAGCCCTTGTGCTTCTCTCACTCTGCATTTTGGCCATTCTCTTCCACTCTTC									
TATA									
Signal sequence									
2110	2120	2130	2140	2150	2160	2170	2180	2190	2200
TCTGGGTAGGCAGCAATTCCAGCAGGGGAACGAGTGCCAGATCGACAGGATCGACGCATCCGAGCCGGACAAAAACCATCCAGGCAGAAAGCTGGCACCATC									
L G R Q Q F Q Q Q G N E C Q I D R I D A S E P D K T I Q A E A G T I									
2210	2220	2230	2240	2250	2260	2270	2280	2290	2300
GAGGTATGGGACGAGAACCGCCAGCAATTCAGTGGCTGGTGTTCGGCTTGTAAGGGCCACCATTGAGCCCAAAGGCTTCTTCTTTCCTTCTACAGCA									
E V W D Q N R Q Q F Q Q C A G V A V R R T I E P K G L L L P F Y S									

FIGURE 4C

2310 2320 2330 2340 2350 2360 2370 2380 2390 2400
ACACCCCTCAGCTCATCTACATCGTTCAAGgtataaaattaaatcagttcatacaatgataaccaccacttgcgaatgtatttatcaaatatcaatgatcgga
N T P Q L I Y I V Q

2410 2420 2430 2440 2450 2460 2470 2480 2490 2500
tgcacctgtatgtgtgtatattcagTAGGGGAGTTACAGGAATCATGTTCCAKGATGTCCAGAGACATTCGAGGAATCCAGCAGCAAGGACAAAC
G R G V T G I M F P X C P E T F E S Q Q Q G Q

2510 2520 2530 2540 2550 2560 2570 2580 2590 2600
AGGGCCAAACAGGGTAGTTCCCAAGACCAGCACCAAGATCCGCCGCTTCCGTGAAGGTGACGTCAATTGCCGTCCTTCCGGTGTAGCCCCACTGGTCCCTA
Q G Q Q G S S Q D Q H Q K I R R F R E G D V I A V P A G V A H W S Y

2610 2620 2630 2640 2650 2660 2670 2680 2690 2700
CAACGATGGCAACGAACCAAGTCATGGCCATTTGTTCATGACACTTCCAGCCACCTCAACCAACTGGACAAACACCCAGGgtatataagcattgcggt
N D G N E P V M A I V V H D T S S H L N Q L D N N P R

2710 2720 2730 2740 2750 2760 2770 2780 2790 2800
agtgctaataaattgcacacaattggaactctattttcagtatctaataactttttcccttttttggcagAACTTCTACTTGGCAGGAACCCCGAGAGAC
N F Y L A G N P R D

2810 2820 2830 2840 2850 2860 2870 2880 2890 2900
GAGTTCGAAACAATCGCAAGGAGGCAGGCTGAGCCGTGGGAGAGTGAAGGTGGACGAGGACGAGGAACCTTCTCAACCTGCAACAACCTCTTCTT
E F E Q S Q Q G G R L S R G E S E G G R G R R E P L Q P A T T S S

2910 2920 2930 2940 2950 2960 2970 2980 2990 3000
GCGGAATCGACTCCAAGCTCATCGGAGGCGTTCAATGTGACGAGAACGTGGCAAGGAGGTACAGAGCGAGAACACACAGAGGCCAGATCGTCCG
C G I D S K L I A E A F N V D E N V A R R L Q S E N D N R G Q I V R

3010 3020 3030 3040 3050 3060 3070 3080 3090 3100
AGTCGAAGGCGAGCTCGACATCGTCAGACCTCCGACCAAGTATCCAGGAGGAGTCAAGGAGGTCGAGGAGGTCGTGGTGGCCGCTACTACTCCAATGGA
V E G E L D I V R P P T S I Q E E S Q E Q G G R G G R Y Y S N G

3110 3120 3130 3140 3150 3160 3170 3180 3190 3200
GTGGAGGAGACCTTCTGCTCCATGAGACTAATTGAGAACATCGGGCATCTTCTCGGGCAGACATTTTCACTCCAGAGCGCGCGTTAGATCCCTCA
V E E T F C S M R L I E N I G D P S R A D I F T P E A G R V R S L

FIGURE 4D

3210 3220 3230 3240 3250 3260 3270 3280 3290 3300
 ACAGCCACAACCTCCCTCGTCAATGGATCCAGCTTAGCGCCGAGAGCGGTTCTCTACAAATgtatagatctcactcacgcaccaactctaaattga
 N S H N L P V L Q W I Q L S A E R G V L Y N
 3310 3320 3330 3340 3350 3360 3370 3380 3390 3400
 atccctaatttaattcaccgatctgaccgaccggtttgaatttttagGAAGCGATCAGGCTGCCGCACTGGAACATCAACGCACACAGCATAGT
 E A I R L P H W N I N A H S I V
 3410 3420 3430 3440 3450 3460 3470 3480 3490 3500
 GTACGCGATCAGAGGACAAGCCAGAGTCCAGATCGTGAACGAGGAAGGGAATTCGGTGTTCGATGGAGTGCCTGCAGGAAGGACAGGTGGTGACCGTGCCG
 Y A I R G Q A R V Q I V N E E G N S V F D G V L Q E G Q V V T V P
 3510 3520 3530 3540 3550 3560 3570 3580 3590 3600
 CAGAACTTCGGGTGGTAAAGAGATCCAGAGCGAGAGGTTTGAGTGGGTGGCGTTCAAGACCAACGACGCGATGGTGAACCTCGCTAGCCGGGAGGA
 Q N F A V V K R S Q S E R F E W V A F K T N D N A M V N S L A G R
 3610 3620 3630 3640 3650 3660 3670 3680 3690 3700
 CATCGGCAGTAAGGGCGATCCCCGGCGGATGTACTGGCTAACGCCCTGGAGGGTGTGCCGAGGAGCGAGGGTGAAGTTCAACAGGCAGGAGACTCA
 T S A V R A I P A D V L A N A W R V S P E A R R V K F N R Q E T H
 3710 3720 3730 3740 3750 3760 3770 3780 3790 3800
 CTTGGCTAGCACCGGGGCCAGTCCAGGTCCCGCGGAGGTTGAATGTCGTCAGGAGGTGATCAACTTGCTTATGTAAaatgtgacggtgaaataataa
 L A S T R G Q S R S P G R L N V V K E V I N L L M *
 3810 3820 3830 3840 3850 3860 3870 3880 3890 3900
 cggtaaaatataataataataaagccacaaagtgagaatgaggggaaggggaaatgtaatgagccagtagcgggtggtgctaatttg
 3910 3920 3930 3940 3950 3960 3970 3980 3990 4000
 tatcgtaattgcaataaatcatgaatttgggtttttatgtgttttttaaatcatgaatttttaaatattataaaataatctccaatcggaagaacaac
 4010 4020 4030 4040 4050 4060 4070 4080 4090 4100
 attccatatccatggatgtttctttaccctaaatctagttctctgagaggatgaagcatcacccgaacagttctgtgcaactatccctcaaaagctttaaaatga
 4110 4120 4130 4140 4150 4160 4170 4180 4190 4200
 acaacaaggaacagagcaacgttccaaagatcccaaacgaaacatatattatctataactataattattataattactactgcccgggaatcaccaatccct

FIGURE 4E

4210 4220 4230 4240 4250 4260 4270 4280 4290 4300
gaatgattcctattactacaagccttgttgccgcgagaaagtgatcgcgcgagcagcgactcgagacgagcccttgatgacagagtc
4310 4320 4330 4340 4350 4360 4370 4380 4390 4400
tttacctccaggcgctgaagggaagagcgcccttctggagtaggagttcagcaagcgcggttcccttgccgagtaagcgacgtaagggtggnctg
4410 4420 4430 4440 4450 4460 4470 4480 4490 4500
gacgtcntcgttcngggagcgnattcatgaagggttaaaagtcanaatctgtagctctcgagtgctcagggagccnaaaagacgcttgggaaaccgtcgcncgt
4510 4520 4530 4540 4550 4560 4570 4580 4590 4600
ttggggcatcagtcngcggggcacgcttccctcctcgtgctccanaancnangtanatttaaaaganatgggaaattaantaatggnaatnannaggagg
4610 4620 4630 4640 4650 4660 4670 4680 4690 4700
attgnaacggtcngancngnangaanagttttannnggtttaaatactgggggagtnagnagccnccnctgggtccngttagangaaacaaagnccgg
4710 4720 4730 4740 4750 4760 4770 4780 4790 4800
gaggttncannngnaggagaaaaagganncattnannangcngaggacatgaancggtacngagctgnggttcannnancggcgnnnngnagtcc
4810 4820 4830 4840 4850 4860 4870 4880 4890 4900
cnngggaccnngntggggtanaagggaanggaacattnggtngnangganaanaaccnttttactnattgccttgcaggnngntnggcncntnccgggt
4910 4920 4930 4940 4950 4960 4970 4980 4990
nacatnccgctgcatgggcttggggngccnanaggagccncanggggnannccncccttgtncangncgtnaagttcnattgtanattggnccgttg

bonds, it is more stable than an A•T base pair, which has only two hydrogen bonds. The more G•C base pairs are contained in a DNA, the greater the energy that is needed to separate the two strands; the T_m increases $\sim 0.4^\circ\text{C}$ for every 1% increase in G•C content. When DNA is in solution under approximately physiological conditions, the T_m usually lies in a

range of $85\text{--}95^\circ\text{C}$. (A DNA that is 40% G•C—a value typical of mammalian genomes—denatures with a T_m of about 87°C under approximately physiological conditions; a DNA that is 60% G•C has a T_m of $\sim 95^\circ\text{C}$ under the same conditions.) Thus without intervention from cellular systems, duplex DNA is stable at the temperature prevailing in the cell.

Nucleic acids hybridize by base pairing


Nucleic acid sequences can be assessed in terms of either similarity or complementarity.

- **Similarity** between two sequences is given in principle by the proportion of bases (for single-stranded sequences) or base pairs (for double-stranded sequences) that is identical. Without determining the actual sequences, however, there is no direct way to measure similarity.
- **Complementarity** is determined by the rules for base pairing between A•T and G•C. In a perfect duplex of DNA, the strands are precisely com-

plementary. If we compare two different but related double-stranded molecules, therefore, each strand of the first molecule will be similar to one strand of the second molecule and will be (partly) complementary to the other strand of the second molecule. Complementarity can be measured directly by the ability of two single-stranded nucleic acids to base pair with each other. If double-stranded molecules are denatured into single strands, the complementarity between the single strands can be used to indicate the similarity between the original duplex molecules.

Figure 5.2

Denatured single strands of DNA can renature to give the duplex form.



It is possible to measure complementarity because the denaturation of DNA is reversible under appropriate conditions. The ability of the two separated complementary strands to reform into a double helix is called **renaturation**. It is illustrated in Figure 5.2.

Renaturation depends on specific base pairing between the complementary strands. The reaction takes place in two stages. First, single strands of DNA in the solution encounter one another by chance; if their sequences are complementary, the two strands base pair to generate a short double-helical region. Then the region of base pairing extends along the molecule by a zipper-like effect to form a lengthy duplex molecule. Renaturation of the double helix restores the original properties that were lost when the DNA was denatured. Renaturation describes the reaction between two complementary sequences that were separated by denaturation. However, the technique can be extended to allow any two complementary nucleic acid sequences to **anneal** with each other to form a duplex structure.

The reaction is generally described as **hybridization** when nucleic acids from different sources are involved, as in the case when one preparation consists of DNA and the other consists of RNA. *The ability of two nucleic acid preparations to hybridize constitutes a precise test for their complementarity since only complementary sequences can form a duplex structure.*


The principle of the hybridization reaction is to expose two single-stranded nucleic acid preparations to each other and then to measure the amount of double-stranded material that forms. There are two common ways of performing the reaction: **solution (liquid) hybridization** and **filter hybridization**.

Liquid hybridization is described by its name: the two preparations of single-stranded DNA are mixed together in solution. When large amounts of material are involved, the reaction can be followed by the change in optical density. With smaller amounts of material, one of the preparations may carry a radioactive label, whose entry into duplex form is followed by determining the amount of double-stranded DNA containing the

label. Double-stranded DNA can be assayed either by using chromatography to separate duplex DNA from single strands or by degrading all the single strands that have not reacted and then

Figure 5.3

Filter hybridization establishes whether a solution of denatured DNA (or RNA) contains sequences complementary to the strands immobilized on the filter.



measuring the amount of material that remains.

Solution hybridization is not an appropriate technique for investigating the relationship of two preparations if one or both consist of duplex DNA. The problem is that if two duplex DNA preparations are denatured and then the single strands are mixed, two types of reaction occur. The *original* complementary single strands can renature. Or each single strand can hybridize with a complementary sequence in the *other* DNA. The competition between the two reactions makes it difficult to assess the extent of hybridization.

This difficulty can be overcome by immobilizing one of the DNA preparations so that it cannot renature. Nitrocellulose filters have the useful property of adsorbing single strands of DNA but not RNA; and once a filter has been used to adsorb DNA, it can be treated to prevent any further adsorption of single strands.

Figure 5.3 illustrates the resulting procedure in which a DNA preparation is denatured and the single strands are adsorbed to the filter. Then a second denatured DNA (or RNA) preparation is added. This material adsorbs to the filter only if it is able to base pair with the DNA that was originally adsorbed. The usual form of the experimental procedure is to add a radioactively labeled RNA or DNA preparation to the filter, allowing the extent of reaction to be measured as the amount of radioactive label retained by the filter.

The extent of hybridization between two single-stranded nucleic acids can be taken in principle to represent their degree of complementarity. Two sequences need not be *perfectly* complementary to hybridize; if they are closely related but not identical, an imperfect duplex is formed in which base pairing is interrupted at positions where the two single strands do not correspond.

Single-stranded nucleic acids may have secondary structure

The stability of the double helix results from the hydrogen bonding between the complementary A-T and G-C pairs and also from interactions between the bases as they are 'stacked' above each other along the axis of the helix. These forces can be used to predict the stability of a double helix between two complementary sequences. Because RNA is the predominant single-stranded nucleic acid, the formation of double-stranded regions from a single strand is usually analyzed in terms of RNA, but the technique is equally valid for single-stranded DNA.

The primary structure of RNA is the same as that of DNA: a polynucleotide chain with 5'-3' sugar-phosphate links. Considered as a single strand, the molecule follows a random path in space, but base pairing within it can fix the location of one region relative to another.

When a sequence of bases is followed by a

complementary sequence nearby in the same molecule, the chain may fold back on itself to generate an antiparallel duplex structure, called a *hairpin*. It consists of a base-paired, double-helical region, the *stem*, with a loop of unpaired bases at one end. Figure 5.4 shows an example. When the complementary sequences are relatively distant in the molecule, their juxtaposition to form a double-stranded region essentially creates a stem with a very long single-stranded loop.

Our ability to measure secondary structure is rather crude. The *overall* extent of base pairing is reflected in the biophysical properties of a molecule. However, this does not reveal which individual regions are involved. Single-stranded and double-stranded regions have different susceptibilities to some nucleases (enzymes that degrade nucleic acids), and this provides a test for analyzing the involvement of particular regions in base